Dra. Teresa Muñoz de Galdeano (ORCiD: 0000-0003-3526-819X). I obtained the Pharmacy´s Degree from the Universidad de Sevilla (2004) and the PhD degree in Pharmacy in the group of Dr. Fernando Valdivieso in Centro de Biología Molecular “Severo Ochoa” (2010), both here in Spain. The field of my research was Familial Alzheimer Disease, and more specifically, the impact of ageing oxidative stress and mutations in amyloid precursor protein gene on neuronal cell survival and metabolism/processing of the amyloid precursor protein (Muñoz, T. et al; 2010). After obtaining the doctoral degree, I started my postdoctoral work at the Hospital Nacional de Parapléjicos, in the Neuroprotección Molecular group (Toledo, Spain), where I’m still working today as senior postdoctoral with a statutory position, under the supervision of Dr. R. Martínez Maza. I’m studying anti-apoptotic and cytoprotective strategies for early treatment against the neurotraumatic damage after spinal cord injury. Among these strategies are included: i) anti-apoptotic role of XIAP protein (Reigada, D., et al. 2015; Caballero-López MJ, et al., 2017), ii) description and regulation of autophagic processes induced after spinal cord injury (Muñoz-Galdeano T, et al. 2018; Klionsky D, et al. 2021). and iii) regulatory role of microRNAs in the deleterious processes induced by spinal cord injury (Yunta, M., et al.,2012; Reigada D, et al., 2019). These advances have allowed me to have a transversal vision of the therapeutic potential of miRNAs in other pathologies, and thus also I am focused on characterizing the miRNAs that are implied in the regulation of the expression of the antiapoptotic and autophagic proteins, in the context of resistance of gynecological cancer cells to chemotherapy treatments (Muñoz-Galdeano, T. et al; in progress).